TWO-YEAR EFFICACY AND SAFETY OF GUSELKUMAB FOR TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: PHASE 3 VOYAGE 1 TRIAL

被引：3
|
作者：
Griffiths, C. E. [1 ]
Papp, K. A. [2 ]
Kimball, A. B. [3 ]
Randazzo, B. [4 ]
Wasfi, Y. [4 ]
Li, S. [4 ]
Shen, Y. -K. [4 ]
Blauvelt, A. [5 ]
机构：
[1] Univ Manchester, Manchester, Lancs, England
[2] K Papp Clin Res & Prob Res Inc, Waterloo, ON, Canada
[3] Beth Israel Deaconess Med Ctr Inc, Harvard Med Fac Phys, Boston, MA USA
[4] Janssen Res & Dev LLC, Spring House, PA USA
[5] Oregon Med Res Ctr, Portland, OR USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.5825
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0912
引用
收藏
页码：1580 / 1581
页数：3
相关论文
共 50 条
  • [41] Maintenance of Efficacy Results from UNCOVER-1: A Phase 3 Trial of Ixekizumab for Moderate-to-Severe Plaque Psoriasis
    Leonardi, C.
    Leutz, A.
    Blauvelt, A.
    Langley, R. G.
    Luger, T.
    Ohtsuki, M.
    Cameron, G. S.
    Erickson, J.
    Zhao, F.
    Shrom, D. S.
    Braun, D.
    Osuntokun, O. O.
    Heffernan, M.
    Nickoloff, B. J.
    Gordon, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 4 - 4
  • [42] Maintenance of efficacy results from UNCOVER-1: A phase 3 trial of ixekizumab for moderate-to-severe plaque psoriasis
    Leonardi, Craig
    Blauvelt, Andrew
    Langley, Richard
    Luger, Thomas
    Ohtsuki, Mamitaro
    Cameron, Gregory S.
    Braun, Daniel
    Erickson, Janelle
    Zhao, Fangyi
    Shrorn, David S.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian
    Gordon, Kenneth
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S16 - S16
  • [43] Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials
    Howell, Seth T.
    Cardwell, Leah A.
    Feldman, Steven R.
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (04) : 380 - 387
  • [44] Safety of treatment with guselkumab in clinical trials for up to 5years in patients with moderate-to-severe plaque psoriasis
    不详
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (01) : E29 - E29
  • [45] Maintenance of response with guselkumab for up to 3 years' treatment in the phase 3 VOYAGE 1 trial of patients with plaque psoriasis
    Griffiths, C. E.
    Papp, K. A.
    Song, M.
    Randazzo, B.
    Li, S.
    Shen, Y. -K.
    Han, C.
    Blauvelt, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 49 - 50
  • [46] Consistent responses to guselkumab by disease region at week 48 in the treatment of moderate-to-severe psoriasis: ECLIPSE trial results
    Langley, R. G.
    Ferris, L.
    Gebauer, K.
    Arenberger, P.
    Gooderham, M.
    Guenther, L.
    Flavin, S.
    Li, S.
    Randazzo, B.
    Armstrong, A.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 58 - 58
  • [47] Two-year safety of apremilast in patients with moderate to severe plaque psoriasis: Results from ESTEEM 1
    Papp, K.
    Reich, K.
    Sobell, J. M.
    Menter, A.
    Lacour, J. P.
    Chimenti, S.
    Hu, C. C.
    Day, R. M.
    Shah, K.
    Griffiths, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 67 - 67
  • [48] Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
    Chiricozzi, Andrea
    Costanzo, Antonio
    Fargnoli, Maria Concetta
    Malagoli, Piergiorgio
    Piaserico, Stefano
    Amerio, Paolo
    Argenziano, Giuseppe
    Balato, Nicola
    Bardazzi, Federico
    Bianchi, Luca
    Carrera, Carlo Giovanni
    Conti, Andrea
    Dapavo, Paolo
    De Simone, Clara
    Loconsole, Francesco
    Lo Schiavo, Ada
    Malara, Giovanna
    Musumeci, Maria Letizia
    Parodi, Aurora
    Peris, Ketty
    Prignano, Francesca
    Rongioletti, Franco
    Talamonti, Marina
    Potenza, Concetta
    EUROPEAN JOURNAL OF DERMATOLOGY, 2021, 31 (01) : 3 - 16
  • [49] Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
    Andrea Chiricozzi
    Antonio Costanzo
    Maria Concetta Fargnoli
    Piergiorgio Malagoli
    Stefano Piaserico
    Paolo Amerio
    Giuseppe Argenziano
    Nicola Balato
    Federico Bardazzi
    Luca Bianchi
    Carlo Giovanni Carrera
    Andrea Conti
    Paolo Dapavo
    Clara De Simone
    Francesco Loconsole
    Ada Lo Schiavo
    Giovanna Malara
    Maria Letizia Musumeci
    Aurora Parodi
    Ketty Peris
    Francesca Prignano
    Franco Rongioletti
    Marina Talamonti
    Concetta Potenza
    European Journal of Dermatology, 2021, 31 : 3 - 16
  • [50] Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year
    Galluzzo, Marco
    Talamonti, Marina
    Bernardini, Nicoletta
    Chiricozzi, Andrea
    De Simone, Clara
    Bonifati, Claudio
    Bruni, Pierluigi
    Diotallevi, Federico
    Esposito, Maria
    Graceffa, Dario
    Hansel, Katharina
    Loconsole, Francesco
    Moretta, Gaia
    Mugheddu, Cristina
    Papini, Manuela
    Richetta, Antonio
    Skroza, Nevena
    Atzori, Laura
    Fargnoli, Maria Concetta
    Persechino, Severino
    Offidani, Annamaria
    Stingeni, Luca
    Peris, Ketty
    Potenza, Concetta
    Bianchi, Luca
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (12) : 1585 - 1592
12345